Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993

Ingrid J.G. Burvenich; Christian Wichmann; Alexander Franklin McDonald; Nancy Guo; Angela Rigopoulos; Nhi Huynh; Mary E. Vail; Stacey Allen; Graeme O’Keefe; Fiona E. Scott; Raul Soikes; Steven Angelides; Reinhard von Roemeling; Andrew M. Scott

doi:10.1007/s00259-024-06854-z

July 26, 2024European Journal of Nuclear Medicine and Molecular ImagingOpen Access

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993

View Full Paper

Ask AI

Bookmark

Share

Abstract

CI-8993 is a fully human IgG1κ monoclonal antibody (mAb) that binds specifically to immune checkpoint molecule VISTA (V-domain Ig suppressor of T-cell activation). Phase I safety has been established in patients with advanced cancer (NCT02671955). To determine the pharmacokinetics and biodistribution of CI-8993 in patients, we aimed to develop

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Burvenich et al. (2024) studied this question.

synapsesocial.com/papers/68e5ee87b6db64358758308d https://doi.org/10.1007/s00259-024-06854-z

View Full Paper

Ask AI

Bookmark

Share

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993

Abstract

Discussion

Cite This Study

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from European Journal of Nuclear Medicine and Molecular Imaging

Keep reading

More related papers

More from European Journal of Nuclear Medicine and Molecular Imaging